Terns Pharmaceuticals Inc [TERN] stock is trading at $7.06, down -5.11%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TERN shares have gain 2.47% over the last week, with a monthly amount glided 16.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 31, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $82 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $16 on June 22, 2023. Jefferies initiated its recommendation with a Buy and recommended $18 as its price target on June 07, 2023. ROTH MKM started tracking with a Buy rating for this stock on May 31, 2023, and assigned it a price target of $23. In a note dated May 08, 2023, BMO Capital Markets initiated an Outperform rating and provided a target price of $18 on this stock.
Terns Pharmaceuticals Inc [TERN] stock has fluctuated between $1.87 and $11.40 over the past year. Currently, Wall Street analysts expect the stock to reach $15.4 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $7.06 at the most recent close of the market. An investor can expect a potential return of 118.13% based on the average TERN price forecast.
Analyzing the TERN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.27 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.68 points at the first support level, and at 6.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.53, and for the 2nd resistance point, it is at 8.01.
Ratios To Look Out For
For context, Terns Pharmaceuticals Inc’s Current Ratio is 24.70. As well, the Quick Ratio is 24.70, while the Cash Ratio is 11.3.
Transactions by insiders
Recent insider trading involved Kuriakose Emil, Chief Medical Officer, that happened on Jul 01 ’25 when 853.0 shares were sold. Chief Financial Officer, Gengos Andrew completed a deal on Jun 27 ’25 to buy 10000.0 shares. Meanwhile, Chief Executive Officer Burroughs Amy L. bought 23314.0 shares on Jun 25 ’25.
